To further confirm that MYST1 promoted cell proliferation through EGFR activation, we used an EGFR inhibitor, erlotinib, which was used to treat NSCLC, pancreatic cancer and several other types of cancer. Here, KAT8 is linked to familial pancreatic carcinoma.